LONDON, May 8 (newratings.com) - Analysts at JP Morgan reiterate their "overweight" rating on Sanofi-Aventis SA (SNW.ETR), while raising their estimates for the company. The 12-month target price is set to €78.

In a research note published this morning, the analysts mention that the company has reported robust 1Q results, with sales in-line with the consensus. Sanofi-Aventis has raised its profit guidance for FY07. The analysts believe, however, that the company has raised its guidance conservatively. The company is likely to launch its Acomplia drug in 3Q, which might provide a boost to its share price, JP Morgan adds. The EPS estimates for 2007 and 2008 have been raised from €4.95 to €5.20 and from €5.26 to €5.28, respectively. Source: Yahoo News  

(PRLog.Org) – A part of this system is the Endocannabinoid in such a way specified system. It steers among other things the energy balance, the sugar and the fat metabolism as well as the body weight. Besides it plays a role with the desire on very sweet or very fat food.

The Endocannabinoid system is activated, if a hunger feeling begins. If this system is falsely active continuously, feels the concerning increases hunger and many more than necessarily eats.

Rimonabant is a CB1-Rezeptor blocker. It normalizes the overactivity of the Endocannabinoid of system.

Rimonabant should be used only with strong predominance (BMI = 30), if calorie-poor food, change of the eating habits and the movement did not have the desired effect and additional factors of risk for heart cycle illnesses to exist as for instance diabetes type of 2 or high blood fat values.

The most important, well-known side effects are listed. They can occur, do not have however not, since each humans respond differently to medicines.
Visit http://acomplia.smyr.se/rimonabant.html